J
John Seibyl
Researcher at Yale University
Publications - 340
Citations - 28040
John Seibyl is an academic researcher from Yale University. The author has contributed to research in topics: Spect imaging & Dopamine transporter. The author has an hindex of 71, co-authored 320 publications receiving 25065 citations. Previous affiliations of John Seibyl include University of Rochester & Temple University.
Papers
More filters
Journal ArticleDOI
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
John H. Krystal,Laurence P. Karper,John Seibyl,Glenna K. Freeman,Richard C. Delaney,J. Douglas Bremner,George R. Heninger,Malcolm B. Bowers,Dennis S. Charney +8 more
TL;DR: These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.
Journal ArticleDOI
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder.
J. Douglas Bremner,Penny Randall,Tammy Scott,Richard A. Bronen,John Seibyl,Steven M. Southwick,Richard C. Delaney,Gregory McCarthy,Dennis S. Charney,Robert B. Innis +9 more
TL;DR: A smaller right hippocampal volume in PTSD that is associated with functional deficits in verbal memory is consistent with high levels of cortisol associated with stress.
Journal ArticleDOI
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.
Journal ArticleDOI
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
Marc Laruelle,Anissa Abi-Dargham,C H van Dyck,Roberto Gil,Cyril D'Souza,Joseph Erdos,Elinore McCance,W Rosenblatt,Christine L Fingado,Sami S. Zoghbi,R. M. Baldwin,John Seibyl,John H. Krystal,Dennis S. Charney,Robert B. Innis +14 more
TL;DR: In the schizophrenic group, elevated amphetamine effect on [123I]IBZM binding potential was associated with emergence or worsening of positive psychotic symptoms, suggesting that psychotic symptoms elicited in this experimental setting in schizophrenia patients are associated with exaggerated stimulation of dopaminergic transmission.
Journal Article
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway,Ira Shoulson,K. Kieburtz,Michael P. McDermott,Pierre N. Tariot,Cornelia Kamp,Denni Day,Aileen Shinaman,S. Fahn,Anthony E. Lang,Kenneth Marek,John Seibyl,W. Weiner,M. Welsh,R. Pahwa,S. Coe,L. Barclay,L. Sutherland,K. Hildebrand,J. Hubble,C. Weeks,P. LeWitt,J. Miyasaki,J. Duff,E. Sime,O. Suchowersky,Mark Stacy,M. Kurth,M. Brewer,M. Harrigan,D. S. Russell,B. Fussell,B. Ford,S. Dillon,J. Hammerstad,C. Stone,D. Riley,P. Rainey,David G. Standaert,M. Tennis,F. Wooten,E. Rost-ruffner,S. Factor,D. Brown,Joseph Jankovic,F. Atassi,Roger Kurlan,Irenita Gardiner,M. Panisset,D. Amyot,J. Hall,A. Rajput,Theresa Shirley,Robert L. Rodnitzky,J. Dobson,C. Shults,D. Fontaine,C. Waters,S. Schuman,R. Pfeiffer,Shirley A. Rast,B. Pfeiffer,Alicia Brocht,Cindy Casaceli,Susan Daigneault,Karen Hodgeman,K. Honsinger,C. O'Connell,Arthur Watts +68 more
TL;DR: Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001).